NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $16.10 +0.15 (+0.91%) As of 10:22 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fulgent Genetics Stock (NASDAQ:FLGT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fulgent Genetics alerts:Sign Up Key Stats Today's Range$15.76▼$16.1450-Day Range$13.79▼$16.8252-Week Range$13.46▼$31.04Volume48,704 shsAverage Volume500,067 shsMarket Capitalization$479.12 millionP/E RatioN/ADividend YieldN/APrice Target$27.00Consensus RatingHold Company Overview Fulgent Genetics, Inc. (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times. Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics. The company offers both clinician-ordered and direct-to-consumer testing models, as well as custom research services for biopharmaceutical partners and academic institutions. Through proprietary automation and AI-driven analytical pipelines, Fulgent aims to maintain cost-effective operations and high data quality for clients across the United States and select international markets. Founded in 2011 by Ming Hsieh, Fulgent Genetics completed its initial public offering in 2019, expanding its capacity and geographic reach. Under the leadership of founder and chairman Ming Hsieh and an experienced management team, the company continues to invest in laboratory automation, informatics enhancements and strategic partnerships. Fulgent remains committed to regulatory compliance, quality assurance and ongoing innovation in molecular diagnostics to support personalized medicine and population health initiatives.AI Generated. May Contain Errors. Read More Fulgent Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreFLGT MarketRank™: Fulgent Genetics scored higher than 64% of companies evaluated by MarketBeat, and ranked 325th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialFulgent Genetics has a consensus price target of $27.00, representing about 67.6% upside from its current price of $16.11.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.81) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulgent Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.17% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 6.28.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.45 News SentimentFulgent Genetics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.Search Interest8 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows4 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLGT Stock News HeadlinesFulgent Genetics Announces Acquisition of CSI LaboratoriesMay 13 at 8:20 AM | businesswire.comLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmMay 8, 2026 | financialpost.comFBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 14 at 1:00 AM | Weiss Ratings (Ad)Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmMay 8, 2026 | globenewswire.comFulgent Genetics, Inc. Q1 2026 Earnings Call SummaryMay 2, 2026 | finance.yahoo.comFulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...May 2, 2026 | finance.yahoo.comFulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call TranscriptMay 1, 2026 | seekingalpha.comFulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual MeetingApril 22, 2026 | businesswire.comSee More Headlines FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $26.27 on January 1st, 2026. Since then, FLGT stock has decreased by 38.7% and is now trading at $16.1050. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its quarterly earnings data on Friday, February, 27th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.14. The firm earned $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative net margin of 23.04% and a negative trailing twelve-month return on equity of 3.24%. Read the conference call transcript. Does Fulgent Genetics have any subsidiaries? Fulgent Genetics subsidiaries include Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Top institutional shareholders of Fulgent Genetics include Dimensional Fund Advisors LP (2.26%), Bank of New York Mellon Corp (0.26%), Y Intercept Hong Kong Ltd (0.23%) and Hsbc Holdings PLC (0.22%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Paul Kim and Jian Xie. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET). Company Calendar Last Earnings2/27/2026Today5/14/2026Next Earnings (Estimated)7/31/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 FLGT's financial health is in the Red zone, according to TradeSmith. FLGT has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,315Year Founded2011Price Target and Rating Average Price Target for Fulgent Genetics$27.00 High Price Target$36.00 Low Price Target$15.00 Potential Upside/Downside+67.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.51 million Net Margins-23.04% Pretax Margin-26.31% Return on Equity-3.24% Return on Assets-2.97% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31 Sales & Book Value Annual Sales$322.67 million Price / Sales1.48 Cash FlowN/A Price / Cash FlowN/A Book Value$35.10 per share Price / Book0.46Miscellaneous Outstanding Shares29,750,000Free Float18,985,000Market Cap$479.12 million OptionableOptionable Beta0.88 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:FLGT) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe US sanctioned itself out of world reserve status…Russia and Iran are both bypassing the US petrodollar - settling oil trades in alternative currencies while ce...Golden Portfolio | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredYour temporary download link is expiringBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
